News Sentiment

VIVS sentiment intelligence

VivoSim Labs, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.58 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-34.1% over one week, -47.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction -34.1% Price reacting lower
Trend fit Trend inactive -47.4% over four weeks
Fair value -91.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 32
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
TradingView 7
MT Newswires 3
Quiver Quantitative 3
StocksToTrade 3
GlobeNewswire 2
Sahm 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 21
Guidance 3
Deals and strategy 1
Balance sheet 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
GlobeNewswire Direct company coverage

VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

VivoSim Labs, Inc. announced its first commercial sales in China for its NAMkind™ toxicology screening and efficacy testing services, marking a significant expansion into the world's second-largest pharmaceutical market. The initial engagements involve a Shanghai-based oncology b

Tone
Positive 81/100
Event
Market update
Published
22 Jul 2026 03:10
Source
GlobeNewswire
TradingView Direct company coverage

VivoSim Labs Prices $4.0 Million Private Placement and Amends Legacy Armistice Warrants

VivoSim Labs (VIVS) announced a $4.0 million private placement consisting of pre-funded and common warrants, with proceeds intended for working capital and general corporate purposes. The company engaged A.G.P./Alliance Global Partners as the placement agent. Additionally, VivoSi

Tone
Positive 60/100
Event
Market update
Published
17 Jul 2026 12:40
Source
TradingView
Bitget Direct company coverage

VivoSim Labs prices USD 4 million private placement at USD 0.85 per share

VivoSim Labs has priced a $4 million private placement at $0.85 per share and warrant with a single healthcare-focused institutional investor. The deal includes 4,705,883 common shares and warrants, with the warrants becoming exercisable after shareholder approval and expiring in

Tone
Positive 69/100
Event
Deals and strategy
Published
17 Jul 2026 02:40
Source
Bitget
Quiver Quantitative Direct company coverage

VivoSim Labs Announces $4.0 Million Private Placement with Institutional Investor and Warrant Amendment

VivoSim Labs has secured $4.0 million through a private placement with a healthcare-focused institutional investor, involving the sale of common stock and warrants at $0.85 per share. Existing warrants will also be amended to lower their exercise price to $0.85, subject to shareh

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 01:40
Source
Quiver Quantitative
Investing.com Direct company coverage

VivoSim Labs raises $4M in private placement

VivoSim Labs (NASDAQ:VIVS) has raised approximately $4.0 million through a private placement with a healthcare-focused institutional investor, selling shares and warrants at $0.85 per share. The company will use these proceeds for working capital and general corporate purposes. T

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 00:40
Source
Investing.com
www.marketscreener.com Direct company coverage

VivoSim Labs, Inc. announced that it expects to receive $4.000001 million in funding

VivoSim Labs, Inc. has announced a securities purchase agreement with a healthcare-focused institutional investor for $4,000,000.55 in gross proceeds. This funding involves the sale of 4,705,883 common shares and pre-funded warrants, with an issue price and exercise price of $0.8

Tone
Positive 64/100
Event
Guidance
Published
16 Jul 2026 13:09
Source
www.marketscreener.com
Sahm Direct company coverage

Why Vivosim Labs Shares Are Rocketing on Wednesday?

VivoSim Labs Inc. (NASDAQ: VIVS) shares surged on Wednesday due to a $5 million milestone payment received from Eli Lilly and Company (NYSE: LLY) and optimistic revenue guidance for FY2027, anticipating over 500% growth. The payment was triggered by the first patient being dosed

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 10:12
Source
Sahm
Moomoo Direct company coverage

VivoSim Labs Sees FY27 Rev Growing Significantly >VIVS

VivoSim Labs (VIVS) projects significant revenue growth for fiscal year 2027. The company's outlook indicates a strong financial performance in the coming years. This forecast suggests positive momentum for VIVS.

Tone
Neutral 50/100
Event
Guidance
Published
16 Jul 2026 02:10
Source
Moomoo
Investing.com Direct company coverage

Why is VivoSim Labs stock sliding today?

VivoSim Labs (VIVS) stock slid 1.5% in after-hours trading, reversing an intraday surge. The initial rally was triggered by a $5 million milestone payment from Eli Lilly and a projection of over 500% revenue growth for fiscal year 2027 due to demand for its NAMkind 3D cellular mo

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 00:15
Source
Investing.com
TechStock² Direct company coverage

VivoSim Labs (NASDAQ:VIVS) hits $5M milestone; company says 500% revenue jump comes off $131K base

VivoSim Labs (NASDAQ:VIVS) received a $5 million milestone payment from Eli Lilly and Company (NYSE:LLY) after the first patient was dosed in a Phase 2 trial for an inflammatory bowel drug. Despite this significant payment, which is 1.7 times VivoSim’s equity value, shares closed

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 21:15
Source
TechStock²
Investing.com Nigeria Direct company coverage

VivoSim receives $5M milestone payment from Eli Lilly By Investing.com

VivoSim Labs Inc. (NASDAQ:VIVS) announced today it has received a $5 million milestone payment from Eli Lilly related to a former inflammatory bowel disease drug program. This payment marks the dosing of the first patient in Phase 2 studies of the drug, with potential for up to $

Tone
Positive 81/100
Event
Market update
Published
15 Jul 2026 20:12
Source
Investing.com Nigeria
grafa.com Direct company coverage

VivoSim receives $5 million Eli Lilly milestone

VivoSim received a $5 million milestone payment from Eli Lilly after the first patient was dosed in Phase 2 studies for an acquired inflammatory bowel disease (IBD) drug. VivoSim, which sold its FXR314 IBD program to Eli Lilly in March 2025, could earn an additional $45 million i

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 17:15
Source
grafa.com
StocksToTrade Direct company coverage

VIVS Stock Whipsaws As Traders Target Volatile Moves

VivoSim Labs Inc. (VIVS) stock is experiencing extreme volatility, with prices swinging dramatically from premarket spikes to sharp intraday drops. The company, an early-stage story with minimal revenue ($40,000 quarterly) and significant losses (net loss of $5.76M), is attractin

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 14:08
Source
StocksToTrade
Market source Direct company coverage

VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027

VivoSim Labs, Inc. announced receipt of a $5 million milestone payment from Eli Lilly related to an inflammatory bowel disease drug program previously sold to Lilly, triggered by the dosing of the first patient in Phase 2 studies. VivoSim remains eligible for up to an additional

Tone
Neutral 50/100
Event
Guidance
Published
15 Jul 2026 12:15
Source
Market source
www.timothysykes.com Direct company coverage

VIVS Stock Whipsaws As Traders Zero In On Cash Runway

VivoSim Labs Inc. (VIVS) stock experienced significant volatility, driven by news of an AI partnership. Despite low revenue ($40,000) and substantial net losses ($5.76M), the company maintains a cash buffer of $5.0M and low debt, attracting speculative traders due to its early-st

Tone
Neutral 50/100
Event
Balance sheet
Published
15 Jul 2026 09:18
Source
www.timothysykes.com
Stock Titan Direct company coverage

First Phase 2 Patient Brings VivoSim a $5M Lilly Payment

VivoSim (VIVS) announced it received a $5 million milestone payment from Eli Lilly, contingent on the first patient dosing in Phase 2 studies for an inflammatory bowel disease drug VivoSim previously sold. The company is eligible for an additional $45 million in milestones and pr

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 08:05
Source
Stock Titan
KTVB Direct company coverage

VivoSim: Fiscal Q4 Earnings Snapshot

VivoSim Labs, Inc. (VIVS) reported a fiscal fourth-quarter net loss of $5.8 million, or $2.21 per share, with revenues of $40,000. For the full year, the company's loss totaled $13.8 million, or $5.35 per share, on revenues of $131,000. VivoSim Labs is a development-stage company

Tone
Negative 20/100
Event
Earnings
Published
14 Jul 2026 21:10
Source
KTVB